Share information
295.20 €
+1.34 %
12/11/2026 17:35
+1.34 %
Open
High
Low
Volume
293.80 €
297.30 €
291.60 €
174,664
Latest News
09-Nov-2026
BE BOLD: BIMZELX[®] (bimekizumab-bkzx) builds on superior joint responses versus SKYRIZI[®] (risankizumab) at Week 16, with clinical improvements sustained through Week 24
09-Nov-2026
BE BOLD: BIMZELX[[®]] (bimekizumab-bkzx) builds on superior joint responses versus SKYRIZI[®] (risankizumab) at Week 16, with clinical improvements sustained through Week 24
09-Nov-2026
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
04-Nov-2026
UCB advances its digital antibody engineering program with new Cradle collaboration